Related Experiment Video
Updated: Feb 2, 2026

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
Published on: April 11, 2019
Adverse Effects of Treatment with Valproic Acid during the Neonatal Period
E Baudou1, J Benevent2, J L Montastruc2
1Service de Neurologie Pédiatrique, Hôpital des Enfants, Toulouse Cedex, France.
Insights
Valproic acid (VPA) use in newborns can cause serious adverse effects like hyperammonemic encephalopathy and hematological issues. These effects were reversible upon VPA discontinuation, highlighting the need for careful monitoring in neonates.
Area of Science:
- Neonatal Medicine
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Valproic acid (VPA) is infrequently used in neonates.
- Serious adverse effects of VPA are more common in children under two years old.
Purpose of the Study:
- To document adverse effects in full-term newborns treated with VPA.
- To provide guidance on VPA use and monitoring in neonates.
Main Methods:
- Retrospective study of full-term newborns treated with VPA for neonatal seizures.
- Analysis of adverse events and treatment outcomes between 2004 and 2014.
Main Results:
- Five out of 123 newborns (4%) discontinued VPA due to adverse effects.
- Adverse effects included hyperammonemic encephalopathy (n=2) and hematological alterations (n=2).
- No cases of liver toxicity or exacerbation of metabolic diseases were observed.
Conclusions:
- VPA-induced hyperammonemic encephalopathy is a potentially lethal complication requiring vigilant monitoring.
- Adverse effects of VPA in newborns were reversible upon treatment cessation.
- Precautions for VPA implementation and follow-up in newborns are necessary.
Introduction:
Valproic acid (VPA) is rarely used in neonatal period. In children under 2 years old, serious adverse effects are appear to be more frequent.
Aim:
The aim of our study is to report the adverse effects observed in a population of full-term newborns treated with VPA.
Method:
Full-term newborns, hospitalized at the Toulouse CHU, who presented with neonatal seizures and who received long-term treatment with VPA between 2004 and 2014 were included.
Results:
For 5 of the 123 newborns treated with VPA, treatment had to be discontinued due to adverse effects. Three patients presented with disturbances in consciousness within 48 hours of treatment initiation, one case with a moderate overdose and two with hyperammoniemia (157 and 327 μmol/L) without any drug overdose or underlying liver or metabolic disease (VPA-induced hyperammonemic encephalopathy). Two patients presented with secondary hematological alterations. No patient presented with liver toxicity or exacerbation of an underlying metabolic disease.
Conclusion:
While the serious adverse effects of VPA noted were all reversible with the discontinuation of the treatment, the occurrence of encephalopathies with hyperammoniemia is a serious complication that is potentially lethal and calls for close clinical monitoring of newborns treated with valproate. We provide precautions for the implementation and follow-up of VPA in newborns.
More Related Videos
Related Concept Videos
Effective Value of a Periodic Waveform
The effective value of a periodic current represents the direct current (DC) that conveys the same average power to a resistor as the periodic current itself. This concept is crucial when assessing AC circuits. To determine the...
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Substituent Effects on Acidity of Carboxylic Acids
The Periodic Table

